Company Description
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves’ disease and thyroid eye disease.
It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes.
Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021.
The company was incorporated in 2019 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2022 |
| IPO Date | Oct 25, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Jeffrey Finer |
Contact Details
Address: 250 East Grand Avenue South San Francisco, California 94080 United States | |
| Phone | 650 338 3533 |
| Website | septerna.com |
Stock Details
| Ticker Symbol | SEPN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001984086 |
| CUSIP Number | 81734D104 |
| ISIN Number | US81734D1046 |
| Employer ID | 84-3891440 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey T. Finer M.D., Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Elizabeth P. Bhatt M.B.A., M.S. | Chief Operating Officer |
| Samira Shaikhly | Chief People Officer |
| Dr. Daniel Long DPHIL | Senior Vice President of Drug Discovery |
| Uwe Klein Ph.D. | Senior Vice President of Biological Sciences |
| Dr. Robert J. Lefkowitz M.D. | Co-Founder and Member of Cross-Functional Scientific and Drug Discovery Advisory Board |
| Dr. Arthur Christopoulos BPHARM, Ph.D. | Co-Founder and Member of Cross-Functional Scientific and Drug Discovery Advisory Board |
| Dr. Patrick Sexton Ph.D. | Co-Founder and Member of Cross-Functional Scientific and Drug Discovery Advisory Board |
| Ran Xiao C.F.A., M.B.A. | Interim Chief Financial Officer and Vice President of Finance and Business Operations |
| Richard Hansen Ph.D. | Vice President of Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 8-K | Current Report |
| Nov 20, 2024 | 10-Q | Quarterly Report |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 25, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 25, 2024 | 424B4 | Prospectus |